Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice

Drug Metabolism and Disposition

Volumn 38, Issue 5, 2010, Pages 871-878

  Li, Feng ^a   Wang, Laiyou ^a   Guo, Grace L ^a   Ma, Xiaochao ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON; CYTOCHROME P450; CYTOCHROME P450 3A4; DRUG METABOLITE; RITONAVIR; TIPRANAVIR;

ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; DEALKYLATION; ENZYME METABOLISM; FECES; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; METABOLOMICS; MOUSE; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE;

ANIMAL STRUCTURES; ANIMALS; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOCATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DEALKYLATION; DRUG INTERACTIONS; FECES; HUMANS; HYDROXYLATION; METABOLOMICS; MICE; MICE, INBRED STRAINS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PRINCIPAL COMPONENT ANALYSIS; PYRIDINES; PYRONES; RECOMBINANT PROTEINS; RITONAVIR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE DISTRIBUTION;

MUS; PEPPER GOLDEN MOSAIC VIRUS - [MEXICO];

EID: 77950947376     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030817     Document Type: Article

References (24)

1. Brandon EF, Sparidans RW, Guijt KJ, Löwenthal S, Meijerman I, Beijnen JH, and Schellens JH (2006) In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs 24:3-14. (Pubitemid 43163421)
2. Brandon EF, van Ooijen RD, Sparidans RW, Lázaro LL, Heck AJ, Beijnen JH, and Schellens JH (2005) Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. J Mass Spectrom 40:821-831.
3. Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, López P, Clumeck N, Gerstoft J, Stavrianeas N, et al. (2006) Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 43:1347-1356.
4. Chan-Tack KM, Struble KA, and Birnkrant DB (2008) Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System. AIDS Patient Care STDS 22:843-850.
5. Chen C, Gonzalez FJ, and Idle JR (2007a) LC-MS-based metabolomics in drug metabolism. Drug Metab Rev 39:581-597.
6. Chen C, Meng L, Ma X, Krausz KW, Pommier Y, Idle JR, and Gonzalez FJ (2006) Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J Pharmacol Exp Ther 318:1330-1342.
7. Chen L, Sabo JP, Philip E, Mao Y, Norris SH, MacGregor TR, Wruck JM, Garfinkel S, Castles M, Brinkman A, et al. (2007b) Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir. Antimicrob Agents Chemother 51:2436-2444.
8. Courter JD, Girotto JE, and Salazar JC (2008) Tipranavir: a new protease inhibitor for the pediatric population. Expert Rev Anti Infect Ther 6:797-803.
9. Eagling VA, Back DJ, and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
10. Ernest CS, 2nd, Hall SD, and Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591.
11. Giri S, Idle JR, Chen C, Zabriskie TM, Krausz KW, and Gonzalez FJ (2006) A metabolomic approach to the metabolism of the areca nut alkaloids: arecoline and arecaidine in the mouse. Chem Res Toxicol 19:818-827.
12. Hsu A, Granneman GR, and Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275-291.
13. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, et al. (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654-660.
14. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, and Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552-561.
15. Ma X, Chen C, Krausz KW, Idle JR, and Gonzalez FJ (2008) A metabolomic perspective of melatonin metabolism in the mouse. Endocrinology 149:1869-1879. (Pubitemid 351468324)
16. MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, and McCallister S (2004) Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials 5:371-382. (Pubitemid 40253637)
17. Macha S, Chen L, Norris SH, Philip E, Mao Y, Silverstein H, Struble C, and Beers W (2007) Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats. J Pharm Pharmacol 59:1223-1233. (Pubitemid 47359901)
18. McCallister S, Valdez H, Curry K, MacGregor T, Borin M, Freimuth W, Wang Y, and Mayers DL (2004) A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 35:376-382.
19. Pham PA (2005) FDA approves Aptivus (tipranavir). Hopkins HIV Rep 17:6-7.
20. Temesgen Z and Feinberg J (2007) Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 45:761-769. (Pubitemid 47381280)
21. Thomas GH (2001) Metabolomics breaks the silence. Trends Microbiol 9:158.
22. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, and Shader RI (1998) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 38:106-111.
23. Vourvahis M and Kashuba AD (2007) Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 27:888-909. (Pubitemid 46849432)
24. Weckwerth W (2003) Metabolomics in systems biology. Annu Rev Plant Biol 54:669-689.